Continuous glucose monitors (CGMs) are moving beyond their traditional role in type 1 diabetes care and into type 2 diabetes management, offering patients real-time insights into how food, sleep, and stress affect their blood sugar. For decades, CGMs were primarily used by people with type 1 diabetes, but emerging research and new implementation strategies are changing that picture. In Belgium, approximately 80% of type 1 diabetes patients use CGMs, and similar adoption rates are now being explored for type 2 diabetes, where the technology could help millions manage their condition more effectively .

What Makes CGMs Different From Traditional Glucose Testing?

If you've ever pricked your finger for a blood glucose test, you know it captures just a single moment in time. CGMs work differently. Instead of a snapshot, they provide a continuous stream of data throughout the day and night, measuring glucose levels in the fluid under your skin every few minutes. This detailed picture reveals patterns that traditional testing misses .

The difference is significant. A standard A1c test (which measures average blood sugar over three months) or periodic fingerstick tests can't show you the full story of your glucose patterns. CGMs provide metrics like mean interstitial glucose levels, glycemic variability (how much your glucose fluctuates), and time spent above and below the normal range. For people with type 2 diabetes, this granular data allows doctors to better evaluate how well treatments are working and whether intensification is needed .

How Can CGM Data Help Type 2 Diabetes Patients?

The expansion of CGMs into type 2 diabetes care opens several practical benefits. At the individual level, patients can observe real-time feedback about how their daily choices influence glucose levels. Eating a large pasta dinner, skipping exercise, or sleeping poorly all show up in the data, creating a powerful incentive for sustained lifestyle changes .

Beyond individual behavior, CGM data is helping clinicians refine how they diagnose and classify type 2 diabetes. The technology enables more precise phenotyping, meaning doctors can better understand the specific characteristics of each patient's condition and tailor treatment accordingly. This personalized approach supports what's called precision medicine, where interventions are matched to individual metabolic profiles rather than applying a one-size-fits-all strategy .

Research also suggests CGMs could play a role in early detection. A large study of 3,634 people without diabetes or prediabetes found that higher time in range (the percentage of time glucose stays in a healthy zone) was associated with lower HbA1c levels, lower carbohydrate intake, and higher protein intake. The study also found that sleep duration was inversely correlated with mean glucose, meaning shorter sleep was linked to higher average glucose levels .

Ways to Integrate CGM Monitoring Into Type 2 Diabetes Management

• Intermittent Monitoring Periods: Rather than continuous year-round use, type 2 diabetes patients may benefit from periodic 15-day monitoring cycles repeated several times per year, making the technology more affordable and practical for broader populations.
• Earlier Initiation at Diagnosis: Starting CGM monitoring at the time of type 2 diabetes diagnosis allows clinicians to establish baseline glucose patterns and identify which patients might need more aggressive treatment from the start.
• Digital Health Platform Integration: Combining CGM data with mobile apps and questionnaires helps identify individuals at risk for type 2 diabetes earlier, improving opportunities for intervention in the prediabetes stage before the condition fully develops.
• Pharmacist-Led Risk Identification: New software tools designed for pharmacists provide easy-to-use methods to identify at-risk individuals at an early stage, expanding access to preventive care beyond traditional doctor's offices.

Several companies, including Belgian start-ups, are developing software and mobile applications to improve how CGM data is interpreted. Some of these tools use artificial intelligence (AI) models to help clinicians and patients make sense of the detailed glucose information, turning raw numbers into actionable insights .

What's Next for CGM Technology?

The sensors themselves are evolving. Next-generation CGM devices are being developed to measure additional biomarkers beyond glucose, such as ketones and lactate, using photonic technology for measurement. These multifunctional sensors could eventually provide an even more comprehensive picture of metabolic health, moving beyond glucose monitoring alone .

The clinical evidence supporting broader CGM use in type 2 diabetes is building. In type 1 diabetes, CGM systems have consistently demonstrated benefits including reductions in dangerous low blood sugar episodes (hypoglycemia), predictive alerts that warn users before problems occur, improved glycemic control, lower A1c levels, and increased time in range. At the population level, CGM use has reduced healthcare utilization, especially emergency room visits, and fewer diabetes-related complications .

While longer-term health outcome studies are still needed to fully establish the utility of CGM monitoring in people without diabetes, the evidence so far suggests the technology has real potential to reshape how type 2 diabetes is managed. The shift from a reactive approach (testing after the fact) to a proactive one (monitoring in real time) could help millions of people better understand their condition and make more informed decisions about diet, activity, and treatment.